Allievi Sara, Mandigers Tim J, Weaver Fred A, Azizzadeh Ali, Piffaretti Gabriele, Schermerhorn Marc L, Magee Gregory A, Gable Dennis R, Lomazzi Chiara, Trimarchi Santi
Section of Vascular Surgery, Cardio Thoracic Vascular Department, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Interdiscip Cardiovasc Thorac Surg. 2025 Jul 3;40(7). doi: 10.1093/icvts/ivaf156.
This study evaluated the short- to longer-term safety and efficacy of extended thoracic endovascular aortic repair for Type B aortic dissection.
We identified acute and subacute Type B dissection between 2010 and 2016 in the Global Registry for Endovascular Aortic Treatment. We stratified the population based on treatment extent: 'non-extended' (1 stent graft deployed), 'extended' (>1 stent graft deployed). Our primary outcomes were in-hospital spinal cord ischaemia and mortality. Secondarily, we evaluated procedure-related complications (endoleak, migration, fracture, compression, reinterventions), sac dynamics, rupture, and all-cause mortality at 1 and 5 years. Sensitivity analysis was performed in patients without prior aortic procedures.
Of 170 procedures, 78 (46%) were extended (median 2 [range 2-5] stent-grafts). Extended and non-extended treatment had similar rates of complicated presentations (53% vs 64%; P = 0.13). Compared with non-extended treatment, extended treatment had similar in-hospital rates of spinal cord ischaemia (2.6% vs 2.2%; P = 1) and mortality (2.6% vs 2.2%, P = 1). Additionally, extended treatment had not statistically different sac expansion rates, (1 year: 14% vs 23%, P =0.80; 5 years: 16% vs 32%, P=0.29) and rupture risk (1 year: 1.3% vs 3.3%, P = 0.63), similar procedure-related complications (endoleak, migration, fracture, compression, reinterventions; all P > 0.05) and all-cause mortality (1 year: 10% vs 7.6%, P=0.54; 5 years: 19% vs 21%, P=0.82). All outcomes remained similar on sensitivity analysis.
Our findings suggest that extended treatment for Type B aortic dissection may be associated with similar procedure-related risks and complications. Future larger studies are needed to define who might benefit from an extended treatment and further optimize patient-specific treatment for aortic dissection.
本研究评估了B型主动脉夹层的胸段主动脉腔内修复术从短期到长期的安全性和有效性。
我们在全球主动脉腔内治疗注册中心中确定了2010年至2016年期间的急性和亚急性B型夹层。我们根据治疗范围对人群进行分层:“非扩展型”(植入1个支架移植物),“扩展型”(植入>1个支架移植物)。我们的主要结局是住院期间脊髓缺血和死亡率。其次,我们评估了手术相关并发症(内漏、移位、骨折、压迫、再次干预)、瘤腔动态变化、破裂以及1年和5年时的全因死亡率。对未接受过先前主动脉手术的患者进行了敏感性分析。
在170例手术中,78例(46%)为扩展型(中位数为2个[范围2 - 5个]支架移植物)。扩展型和非扩展型治疗的复杂表现发生率相似(53%对64%;P = 0.13)。与非扩展型治疗相比,扩展型治疗的住院期间脊髓缺血发生率(2.6%对2.2%;P = 1)和死亡率(2.6%对2.2%,P = 1)相似。此外,扩展型治疗的瘤腔扩张率(1年:14%对23%,P = 0.80;5年:16%对32%,P = 0.29)和破裂风险(1年:1.3%对3.3%,P = 0.63)无统计学差异,手术相关并发症(内漏、移位、骨折、压迫、再次干预;所有P > 0.05)和全因死亡率(1年:10%对7.6%,P = 0.54;5年:19%对21%,P = 0.82)相似。敏感性分析中所有结局仍相似。
我们的研究结果表明,B型主动脉夹层的扩展型治疗可能与相似的手术相关风险和并发症相关。未来需要更大规模的研究来确定谁可能从扩展型治疗中获益,并进一步优化主动脉夹层的个体化治疗。